Entera Bio Ltd. Ordinary Shares
ENTXEntera Bio Ltd. (ENTX) is a biopharmaceutical company focused on developing oral biologic therapies for serious medical conditions. Leveraging its proprietary platform, the company aims to deliver biologic drugs that can be administered orally, offering potential advantages over traditional injectable treatments. Entera Bio’s pipeline includes candidates targeting osteoporosis, hormone deficiencies, and other indications, with an emphasis on improving patient compliance and convenience.
Company News
Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transac...
